Key result
Percutaneous transvenous mitral commissurotomy significantly increased mean mitral valve area from 0.84 to 1.83 cm2 and resulted in a 70% event-free survival over an 8-year follow-up.
Why the study?
Does percutaneous transvenous mitral commissurotomy improve long-term clinical and echocardiographic outcomes in patients with severe symptomatic mitral stenosis?
Population
84 patients with symptomatic severe mitral stenosis, less than moderate mitral regurgitation, and no left…
Design
Cohort
Follow-up
96 months
Authors
Loading...
PTMC may support durable outcomes in severe mitral stenosis; observational data leaves open need for RCTs before practice change.
Cross-Sectional (n=84)
No
Does percutaneous transvenous mitral commissurotomy improve long-term clinical and echocardiographic outcomes in patients with severe symptomatic mitral stenosis?
Absolute Event Rate: 1.83% vs 0.84%
p-value: p=<0.001
Percutaneous transvenous mitral commissurotomy provides sustained clinical and echocardiographic benefits with good event-free survival at 8 years in patients with severe symptomatic mitral stenosis.
Khan et al. (2017) conducted a cross-sectional in Severe symptomatic mitral stenosis (n=84). Percutaneous transvenous mitral commissurotomy (PTMC) vs. Pre-procedure baseline was evaluated on Mitral valve area (MVA) by two-dimensional echocardiography (p=<0.001). Percutaneous transvenous mitral commissurotomy significantly increased mean mitral valve area from 0.84 to 1.83 cm2 and resulted in a 70% event-free survival over an 8-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: